Instrument Inactif

Communiqués Abraxis Bioscience, Inc.

Actions

US00383Y1029

Produits pharmaceutiques

Cours en clôture Nasdaq
- ^USD	-

Communiqués

13/10/10	ABRAXIS BIOSCIENCE : Celgene and Abraxis Announce Shareholder Vote in Favor of Merger	BU
29/07/10	ABRAXIS BIOSCIENCE : and Specialised Therapeutics Announce Approval to Market ABRAXANE for Metastatic Breast Cancer in New Zealand	BU
23/07/10	ABRAXIS BIOSCIENCE : ABRAXANE® Approved for Marketing in Japan for Breast Cancer	BU
08/07/10	ABRAXIS BIOSCIENCE : The Law Office of Joseph Klein Investigates Possible Breach of Fiduciary Duty by the Board of Abraxis BioSciences Inc. - ABII	BU
01/07/10	ABRAXIS BIOSCIENCE : Law Offices of Howard G. Smith Announces Investigation On Behalf of Shareholders of Abraxis BioScience, Inc.	BU
01/07/10	ABRAXIS BIOSCIENCE : Finkelstein Thompson LLP Announces Investigation of Abraxis Bioscience Inc.	BU
30/06/10	ABRAXIS BIOSCIENCE : Ryan & Maniskas, LLP Announces Investigation of Abraxis BioScience, Inc.	BU
30/06/10	ABRAXIS BIOSCIENCE : Tripp Levy PLLC Investigates Buyout of Abraxis BioSciences	BU
30/06/10	ABRAXIS BIOSCIENCE : Celgene va acquérir Abraxis BioScience Inc.	BU
30/06/10	ABRAXIS BIOSCIENCE : Kendall Law Group Investigates Abraxis BioScience Inc. Merger for Shareholders	BU
30/06/10	ABRAXIS BIOSCIENCE : Goldfarb Branham Law Firm LLP Investigating Potentially Unfair Buyout of Abraxis	BU
30/06/10	ABRAXIS BIOSCIENCE : Rigrodsky & Long, P.A. Investigates Abraxis BioScience Inc. Buyout	BU
30/06/10	ABRAXIS BIOSCIENCE : Levi & Korsinsky, LLP Investigates Possible Breach of Fiduciary Duty by the Board of Abraxis BioSciences Inc. - ABII	BU
30/06/10	ABRAXIS BIOSCIENCE : Celgene to Acquire Abraxis BioScience Inc.	BU
08/06/10	ABRAXIS BIOSCIENCE : Among the Toughest Cancers to Treat, New ABRAXANE® Data Demonstrates Potential in Patients with Advanced and Malignant Melanoma	BU
08/06/10	ABRAXIS BIOSCIENCE : ASCO Presentations Offer New Insights into Role of nab®-Chemotherapy Based Breast Cancer Chemotherapy Treatment	BU
05/06/10	ABRAXIS BIOSCIENCE : Results of Phase 3 ABRAXANE® Combination Trial In First-Line Non-Small Cell Lung Cancer Show 31 Percent Improvement In Response Rate Compared With Taxol Combination	BU
01/06/10	ABRAXIS BIOSCIENCE : New Data Demonstrates Potential of ABRAXANE in Difficult-to-Treat Refractory Invasive Bladder Cancer	BU
21/05/10	ABRAXIS BIOSCIENCE : Second Trial with ABRAXANE to Demonstrate Increased Survival in Patients with Advanced Pancreatic Cancer	BU
18/05/10	ABRAXIS BIOSCIENCE : Over 30 Scientific Presentations at ASCO Exploring ABRAXANE's Expanded Potential in Multiple Difficult-to-Treat Cancers	BU
14/05/10	ABRAXIS BIOSCIENCE : Saint John's Trustee & Abraxis Founder Patrick Soon-Shiong, M.D. Receives Distinguished Medical Science Award from the Friends of the National Library of Medicine	BU
30/11/-1	Abraxis Bioscience : La Commission européenne accorde à Abraxis l'autorisation de mise sur le marché d'ABRAXANE pour le traitement du cancer du sein métastatique en Europe	BU
30/11/-1	ABRAXIS BIOSCIENCE : lance Abraxane® dans l'Union Européenne	BU